NA: Not available. Cystic fibrosis (CF) pulmonary disease is characterized by chronic and recurrent infection, and airway inflammation. Colonization and chronic airway infection with bacterial ...
it may be possible to restore cell balance and thus better prevent bacterial infections. These results are published in the American Journal of Respiratory Cell and Molecular Biology. Cystic ...
June 11, 2024 — Chronic lung diseases are often accelerated and exacerbated by polymicrobial infections. An international study has identified two types of these so-called dysbioses in cystic ...
Cystic fibrosis pulmonary disease is characterized by chronic and recurrent infection, airway inflammation, bronchiectasis and progressive obstructive lung physiology. Advances in the treatment of ...
A connection between lung health and kidney function in adults with cystic fibrosis (CF), identifying early urinary markers ...
The National Veterinary Research Institute in Poland reports the first molecular detection of Sarcocystis miescheriana in a ...
Researchers at The University of Manchester in collaboration with Manchester University NHS Foundation Trust (MFT) are launching a new Cystic Fibrosis Innovation Hub to accelerate the development of ...
Vertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
About Cystic Fibrosis Cystic fibrosis (CF) is a progressive genetic disease that causes persistent lung infections and respiratory failure. CF is caused by mutations in the cystic fibrosis ...
Sodium calcium edetate + tobramycin is under clinical development by Respirion Pharmaceuticals and currently in Phase II for Cystic Fibrosis.